

Approval and implementation dates for specific health plans may vary. Please consult the applicable health plan for more details.

Clinical Appropriateness Guidelines

Surgical

Appropriate Use Criteria: Upper Gastrointestinal Endoscopy (Esophagogastroduodenoscopy)

Proprietary

© 2026 Carelon Medical Benefits Management, Inc. All rights reserved.

Table of Contents

Clinical Appropriateness Guidelines

Description and Application of the Guidelines

General Clinical Guideline

Clinical Appropriateness Framework

Simultaneous Ordering of Multiple Diagnostic or Therapeutic Interventions

Repeat Diagnostic Intervention

Repeat Therapeutic Intervention

Upper Gastrointestinal Endoscopy (Esophagogastroduodenoscopy)

Description and Scope

General Recommendations

Definitions

Clinical Indications

General Indications for Upper Endoscopy

Alarm Features: New or not previously evaluated by upper endoscopy

Therapeutic Upper Endoscopy

Endoscopic Evaluation and Management of Upper Gastrointestinal Signs, Symptoms and Conditions

Achalasia

Barrett's Esophagus

Bleeding and Anemia

Caustic Ingestion

Celiac Disease

Crohn's Disease

Duodenal Masses

Dyspepsia

Eosinophilic Esophagitis

Esophageal Malignancies

Esophageal Varices

Gastric Intestinal Metaplasia (GIM)

Gastric Malignancies

Gastric Polyps

Gastroesophageal Reflux Disease (GERD)

Genetic-Familial Conditions Associated with Upper GI Malignancies

Helicobacter pylori

Imaging Abnormalities

Peptic Ulcer Disease (PUD)

Postoperative/Post-procedure Complications

Preoperative Evaluation of Asymptomatic Patients prior to Bariatric Surgery

Exclusions

References

Codes

History

Description and Application of the Guidelines

The Carelon Clinical Appropriateness Guidelines (hereinafter “the Carelon Clinical Appropriateness Guidelines” or the “Guidelines”) are designed to assist providers in making the most appropriate treatment decision for a specific clinical condition for an individual. The Guidelines establish objective and evidence-based criteria for medical necessity determinations, where possible, that can be used in support of the following:

- To establish criteria for when services are medically necessary
- To assist the practitioner as an educational tool
- To encourage standardization of medical practice patterns
- To curtail the performance of inappropriate and/or duplicate services
- To address patient safety concerns
- To enhance the quality of health care
- To promote the most efficient and cost-effective use of services

The Carelon guideline development process complies with applicable accreditation and legal standards, including the requirement that the Guidelines be developed with involvement from appropriate providers with current clinical expertise relevant to the Guidelines under review and be based on the most up-to-date clinical principles and best practices. Resources reviewed include widely used treatment guidelines, randomized controlled trials or prospective cohort studies, and large systematic reviews or meta-analyses. Carelon reviews all of its Guidelines at least annually.

Carelon makes its Guidelines publicly available on its website. Copies of the Guidelines are also available upon oral or written request. Additional details, such as summaries of evidence, a list of the sources of evidence, and an explanation of the rationale that supports the adoption of the Guidelines, are included in each guideline document.

Although the Guidelines are publicly available, Carelon considers the Guidelines to be important, proprietary information of Carelon, which cannot be sold, assigned, leased, licensed, reproduced or distributed without the written consent of Carelon. Use of the Guidelines by any external AI entity without the express written permission of Carelon is prohibited.

Carelon applies objective and evidence-based criteria, and takes individual circumstances and the local delivery system into account when determining the medical appropriateness of health care services. The Carelon Guidelines are just guidelines for the provision of specialty health services. These criteria are designed to guide both providers and reviewers to the most appropriate services based on a patient’s unique circumstances. In all cases, clinical judgment consistent with the standards of good medical practice should be used when applying the Guidelines. Guideline determinations are made based on the information provided at the time of the request. It is expected that medical necessity decisions may change as new information is provided or based on unique aspects of the patient’s condition. The treating clinician has final authority and responsibility for treatment decisions regarding the care of the patient and for justifying and demonstrating the existence of medical necessity for the requested service. The Guidelines are not a substitute for the experience and judgment of a physician or other health care professionals. Any clinician seeking to apply or consult the Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment.

The Guidelines do not address coverage, benefit or other plan specific issues. Applicable federal and state coverage mandates take precedence over these clinical guidelines, and in the case of reviews for Medicare Advantage Plans, the Guidelines are only applied where there are not fully established CMS criteria. If requested by a health plan, Carelon will review requests based on health plan medical policy/guidelines in lieu of the Carelon Guidelines. Use of an FDA-approved or conditionally approved product does not constitute medical necessity or guarantee reimbursement by the respective health plan.

The Guidelines may also be used by the health plan or by Carelon for purposes of provider education, or to review the medical necessity of services by any provider who has been notified of the need for medical necessity review, due to billing practices or claims that are not consistent with other providers in terms of frequency or some other manner.

General Clinical Guideline

Clinical Appropriateness Framework

Critical to any finding of clinical appropriateness under the guidelines for a specific diagnostic or therapeutic intervention are the following elements:

- Prior to any intervention, it is essential that the clinician confirm the diagnosis or establish its pretest likelihood based on a complete evaluation of the patient. This includes a history and physical examination and, where applicable, a review of relevant laboratory studies, diagnostic testing, and response to prior therapeutic intervention.
- The anticipated benefit of the recommended intervention is likely to outweigh any potential harms, including from delay or decreased access to services that may result (net benefit).
- Widely used treatment guidelines and/or current clinical literature and/or standards of medical practice should support that the recommended intervention offers the greatest net benefit among competing alternatives.
- There exists a reasonable likelihood that the intervention will change management and/or lead to an improved outcome for the patient.

Providers may be required to submit clinical documentation in support of a request for services. Such documentation must a) accurately reflect the clinical situation at the time of the requested service, and b) sufficiently document the ordering provider's clinical intent.

If these elements are not established with respect to a given request, the determination of appropriateness will most likely require a peer-to-peer conversation to understand the individual and unique facts that would justify a finding of clinical appropriateness. During the peer-to-peer conversation, factors such as patient acuity and setting of service may also be taken into account to the extent permitted by law.

Simultaneous Ordering of Multiple Diagnostic or Therapeutic Interventions

Requests for multiple diagnostic or therapeutic interventions at the same time will often require a peer-to-peer conversation to understand the individual circumstances that support the medical necessity of performing all interventions simultaneously. This is based on the fact that appropriateness of additional intervention is often dependent on the outcome of the initial intervention.

Additionally, either of the following may apply:

- Current literature and/or standards of medical practice support that one of the requested diagnostic or therapeutic interventions is more appropriate in the clinical situation presented; or
- One of the diagnostic or therapeutic interventions requested is more likely to improve patient outcomes based on current literature and/or standards of medical practice.

Repeat Diagnostic Intervention

In general, repeated testing of the same anatomic location for the same indication should be limited to evaluation following an intervention, or when there is a change in clinical status such that additional testing is required to determine next steps in management. At times, it may be necessary to repeat a test using different techniques or protocols to clarify a finding or result of the original study.

Repeated testing for the same indication using the same or similar technology may be subject to additional review or require peer-to-peer conversation in the following scenarios:

- Repeated diagnostic testing at the same facility due to technical issues
- Repeated diagnostic testing requested at a different facility due to provider preference or quality concerns

- Repeated diagnostic testing of the same anatomic area based on persistent symptoms with no clinical change, treatment, or intervention since the previous study
- Repeated diagnostic testing of the same anatomic area by different providers for the same member over a short period of time

Repeat Therapeutic Intervention

In general, repeated therapeutic intervention in the same anatomic area is considered appropriate when the prior intervention proved effective or beneficial and the expected duration of relief has lapsed. A repeat intervention requested prior to the expected duration of relief is not appropriate unless it can be confirmed that the prior intervention was never administered. Requests for ongoing services may depend on completion of previously authorized services in situations where a patient's response to authorized services is relevant to a determination of clinical appropriateness.

Upper Gastrointestinal Endoscopy (Esophagogastroduodenoscopy)

Description and Scope

This guideline addresses the appropriate use of upper gastrointestinal endoscopy (esophagogastroduodenoscopy or EGD) in the evaluation and management of adult outpatients. It does not address the use of upper endoscopy in emergency departments, inpatient settings, or in pediatric patients aged 17 years or younger.

Currently published guidelines on endoscopy quality indicators note that upper endoscopy should be performed when the information gained or intervention performed will improve patient outcomes and is not indicated when associated risks outweigh any potential patient benefit.

General Recommendations

Proton pump inhibitors (PPI) have become a standard treatment modality by both primary care providers and gastroenterologists over the past 30 years. Many publications and societal guidelines have addressed the safety, efficacy and limitations of this class of medications which are now available without a prescription. Recent reviews of PPI utilization have demonstrated superior efficacy over Histamine-2-receptor-antagonists (H2RA) and/or placebo in the treatment of peptic ulcer disease, peptic ulcer related bleeding, *Helicobacter pylori* eradication, erosive esophagitis, non-erosive esophagitis, and functional dyspepsia. The American College of Gastroenterology (ACG) has addressed the potential risks of PPI use in their 2013 guideline on gastroesophageal reflux disease which appear minimal in the literature. The ACG recommends continued use of PPIs in osteoporotic patients unless there are additional risks for hip fracture, continued use in patients being treated with Clopidogrel as there does not appear to be a risk for adverse cardiovascular events, cautious use of PPIs in patients at risk for *Clostridium difficile* (*C. diff*) infection, and an acknowledgement of potential risk of community-acquired pneumonia during short-term use. **Given their favorable safety profile, widespread availability, and literature-noted superior efficacy to alternative regimens, PPIs are considered first-line treatment when noted in this guideline but may be substituted by alternative anti-secretory agents when documented allergy or intolerance is noted.**

Helicobacter pylori (*H. pylori*) is a widespread bacterial pathogen with markedly variable prevalence across geographic regions and cohorts. The 2017 ACG guidelines on the treatment of *H. pylori* note an association between infection rates and socioeconomic status as well as a higher North American prevalence among African Americans, Hispanic Americans, Native Americans, Alaska natives, those living close to the U.S./Mexico border, and among immigrants from East Asia. Given the causal linkage between *H. pylori* and peptic ulcer disease as well as its classification by the World Health Organization as a carcinogen, the ACG recommends *H. pylori* testing in patients with peptic ulcer disease, mucosa-associated lymphoid tissue (MALT) lymphoma, early gastric cancer and dyspepsia. The ACG similarly makes a strong recommendation to treat all patients who test positive for *H. pylori*, regardless of the initial indication for testing. Several treatment regimens exist and are typically comprised of 2 to 3 antibiotics along with a PPI for a duration of 3 to 14 days. When testing to confirm eradication, the ACG recommends non-invasive testing at least 4 weeks after therapy completion. **Given the known risks of untreated *H. pylori* infection and strong literature base to support eradication, it is assumed that *H. pylori* testing and treatment for positive results (referred to as “*H. pylori* testing/treatment”) will be performed when appropriate, even if not specifically included in the guideline below. Given the widespread availability of non-invasive testing such as the urea-breath test and stool antigens, confirmation of *H. pylori* eradication is not considered an independent indication for upper endoscopy.**

Screening and surveillance indications are included in several of the conditions listed in the current guideline. As the American Society for Gastrointestinal Endoscopy (ASGE) notes in their 2019 guideline on Barrett’s esophagus, an appropriate screening/surveillance strategy should be able to identify individuals who have, “a disease or preclinical condition that predisposes to a disease...[who] are periodically assessed or examined to identify disease at a stage amenable to cure.” The ACG similarly recommends that patients receive adequate

counseling regarding the risks and benefits of surveillance prior to surveillance of Barrett's esophagus which should include consideration of age, life expectancy, and ability to tolerate interventions. **All patients undergoing endoscopy for the indications listed below should participate in a thorough process of informed consent regarding risks and benefits, and ordering providers should pursue endoscopy only when results are expected to direct patient-centered management decisions.**

Race, ethnicity, heritage, and socioeconomic status are frequently described as risk factors for various gastrointestinal conditions. These relationships are often multifactorial and typically reflect epidemiologic data that has identified varying prevalence of *H. pylori* infection and upper GI cancers across different populations. The ASGE released a 2015 guideline on Race and Ethnicity Considerations in GI Endoscopy which emphasized the highly diverse, and often multiracial, population of the U.S. The inclusion of risk factors in this guideline that are based on race, ethnicity, heritage, and socioeconomic status are based on currently available literature and may not always be specifically defined. **It is important to acknowledge that both implicit and explicit bias may impact currently available evidence, and clinicians should assess and document any social determinants of health which may impact an individual's personal risk for disease when considering endoscopic evaluation.**

Definitions

Esophagogastroduodenoscopy (EGD): Procedure that requires the use of a flexible endoscope to examine the esophagus, stomach, and proximal small bowel (duodenum).

Upper GI signs/symptoms: Patient-reported sensations or observable findings that suggest dysfunction of the esophagus, stomach, or proximal small bowel.

Barrett's esophagus (BE): Extension of salmon-colored mucosa into the tubular esophagus extending ≥ 1 cm proximal to the gastroesophageal junction with biopsy confirmation of intestinal metaplasia.

Intestinal metaplasia of the esophagus: Intestinal-type columnar epithelium containing goblet cells that replaces the normal stratified squamous epithelium of the distal esophagus and is diagnostic for Barrett's esophagus.

Gastric intestinal metaplasia (GIM): Abnormal tissue in the stomach believed to be a precancerous lesion; GIM may be found in multiple regions of the stomach (extensive GIM) or a single region (limited GIM) and may be characterized as complete (histology resembles small intestinal cells) or incomplete (histology resembles colonic cells).

Mapping biopsies: Strategy for collecting tissue when assessing the extent of gastric intestinal metaplasia that involves sampling from multiple regions of the stomach, notably from the gastric body (corpus), antrum, and incisura.

Celiac serologic testing: Serum testing for autoantibodies directed against gluten proteins; IgA antibodies against tissue transglutaminase (TG2) are the most sensitive for detecting celiac disease, though other IgA antibodies such as those targeting endomysium (EMA) and gliadin are also commonly used. Patients with celiac disease may also have underlying IgA deficiencies, in which case testing for IgG antibodies against TG2, EMA and gliadin is common.

Complete eradication of intestinal metaplasia (CEIM): The goal endpoint after endoscopic eradication therapy for Barrett's Esophagus with or without dysplasia. CEIM is established when endoscopy is negative for visible Barrett's Esophagus and biopsy specimens are negative for intestinal metaplasia.

Low-grade dysplasia: Cells with normal to mild distortion but still fairly uniform (minimal pleomorphism).

High-grade dysplasia/carcinoma in situ: Cells with mild to marked distortion, highly atypical and varied cell appearance (prominent pleomorphism) but remain within the epithelium and do not invade into the lamina propria.

Clinical Indications

General Indications for Upper Endoscopy

Alarm Features: New or not previously evaluated by upper endoscopy

Upper endoscopy is considered medically necessary in **ANY** of the following scenarios:

- Dysphagia or Odynophagia
- Nausea or vomiting ≥ 7 days
- Unexplained weight loss $\geq 5\%$ of usual weight within the past 12 months
- Anorexia or early satiety
- Upper GI symptoms in patients who have a first-degree relative with upper GI malignancy
- Hematemesis, coffee-ground emesis, or melena

Discussion: Alarm Features

A joint publication on EGD quality indicators by the ACG and ASGE recommends early endoscopy in the presence of alarm features. Although these features are noted to have a low predictive value for upper GI malignancy, they represent common presentations of treatable non-malignant conditions such as malabsorption, structural disease, inflammatory disease, and motility disorders. This indication is intended to address new or persistent symptoms that are otherwise unexplained by clinical evaluation where upper endoscopy is required to determine the presence of suspected upper GI pathology.

Therapeutic Upper Endoscopy

Upper endoscopy is considered medically necessary for the management of **ANY** of the following scenarios:

- Treatment of **bleeding lesions** such as ulcers, tumors, or vascular abnormalities
- **Planned dilation** of a known stenotic lesion of the esophagus, stomach, or duodenum (for eosinophilic esophagitis, please see condition-specific indications)
- **Planned resection** of a known lesion (for routine surveillance, please see condition-specific indications)
- Endoscopic placement of **feeding or drainage tubes**
- Management of upper GI tract **foreign bodies or food impaction**
- **Palliative treatment** for stenosing neoplasms such as ablation or placement of self-expanding metal stents

Discussion: General Therapeutic Indications

The 2015 joint publication on quality indicators for EGD by the ACG and the ASGE notes several broad indications for therapeutic upper endoscopy. These indications may be considered appropriate for the management of various underlying conditions and should be used when non-endoscopic treatment is inadequate. Certain therapeutic interventions have not been included within these general therapeutic indications, including the use of botulinum toxin injections for gastroparesis. The 2011 ASGE guideline on the role of endoscopy in gastroduodenal obstruction and gastroparesis notes insufficient data to make a recommendation regarding the role of botulinum toxin in the treatment of gastroparesis. Similarly, the 2013 ACG Clinical Guideline on the management of gastroparesis makes a strong recommendation based on high-level evidence against intrapyloric injection of botulinum toxin for patients with gastroparesis based on results from randomized controlled trials. Most recently, the 2020 European Society of Gastrointestinal Endoscopy (ESGE) guideline on the endoscopic management of gastrointestinal motility disorders recommends against the use of botulinum toxin injection in the treatment of unselected patients with gastroparesis.

Endoscopic Evaluation and Management of Upper Gastrointestinal Signs, Symptoms and Conditions

Achalasia

In patients with an established diagnosis of achalasia, upper endoscopy is considered medically necessary in **ANY** of the following scenarios:

- Evaluation of **alarm features**
- For endoscopic **dilation**
- For endoscopic injection of **botulinum toxin when patient is unable to undergo dilation or surgical intervention**

Discussion: Achalasia

Achalasia is an esophageal motility disorder that results in loss of coordinated peristalsis and decreased relaxation of the lower esophageal sphincter (LES). The ACG notes that achalasia is a chronic, incurable condition for which all treatments are palliative and aimed at reducing symptoms.

The current ACG, ASGE, and ESGE guidelines on achalasia report high rates of success with pneumatic dilation of the lower esophageal sphincter and emphasize that any patient undergoing pneumatic dilation must be a surgical candidate for repair of possible esophageal perforation which occurs in approximately 2% of cases.

The ACG and ASGE guidelines note high rates of symptom control shortly after Botulinum toxin (Botox) injection into the LES. These effects are short-lived, and a cited meta-analysis reported rates of symptom control at 12 months as 73.3% for dilation and 37.5% for Botox. The ESGE recommends that Botox be considered for short-term symptom relief, while the ACG and ASGE both recommend Botox only for patients who are not candidates for dilation or surgical definitive therapy. The ACG and ESGE also recommend against the use of esophageal stents for the treatment of achalasia.

Achalasia has been associated with an increased risk for squamous cell cancer. However, the ASGE notes that surveillance strategies have not shown improved survival. Therefore, the ACG, ASGE, and ESGE recommend against endoscopic surveillance for esophageal cancer in patients with achalasia.^{94, 128, 136}

Barrett's Esophagus

Screening Endoscopy

One-time screening endoscopy is considered medically necessary in patients **without life-limiting comorbidities who are willing and able to undergo surveillance and eradication treatment** in the following scenario:

- **Individuals** with chronic (weekly symptoms persisting more than 5 years) GERD **AND at least THREE or more** of the following risk factors:
 - Male sex
 - Age 50 years or older
 - Caucasian race
 - Central obesity
 - Current or past history of smoking
 - First-degree relative with history of Barrett's esophagus or esophageal adenocarcinoma

Surveillance Endoscopy for Untreated Barrett's Esophagus

Upper endoscopy is considered medically necessary for patients **without life-limiting comorbidities who are willing and able** to undergo eradication treatment in **ANY** of the following scenarios:

- Barrett's esophagus **without dysplasia**:
 - Repeat endoscopy every 3 years
- Barrett's esophagus reported as "**indefinite for dysplasia**":
 - Repeat endoscopy after 3 months of PPI
 - If repeat endoscopy reported as "indefinite for dysplasia," further surveillance annually until definitive result
- Barrett's esophagus with **low-grade dysplasia**:
 - Repeat endoscopy at 6 months, then annually
 - Once two sequential endoscopies are negative for dysplasia, follow-up every 3 years as Barrett's esophagus without dysplasia
- Barrett's esophagus with **high-grade dysplasia**:
 - Repeat endoscopy at 3-month intervals **only for patients unable to undergo immediate eradication** therapy

Treatment for Established Barrett's Esophagus

Upper endoscopy is considered medically necessary for endoscopic treatment in **ANY** of the following scenarios:

- Endoscopic **resection** of Barrett's esophagus with or without dysplasia
- Endoscopic ablative treatment using radiofrequency ablation or cryoablation may be **performed and repeated until the patient achieves complete eradication of intestinal metaplasia (CEIM)** in **EITHER** of the following scenarios:
 - Low-grade dysplasia
 - High-grade dysplasia

Surveillance Endoscopy after Treatment for Barrett's Esophagus

Upper endoscopy is considered medically necessary in **ANY** of the following scenarios:

- To confirm eradication of intestinal metaplasia
- Following confirmed eradication of **low-grade dysplasia**:
 - Repeat endoscopy at 1 year following CEIM, 3 years following CEIM, and then every 2 years
- Following confirmed eradication of **high-grade dysplasia**:
 - Repeat endoscopy 3, 6, and 12 months following CEIM, then annually

Discussion: Barrett's Esophagus

The ACG lists known risk factors for Barrett's esophagus (BE) as chronic GERD symptoms, first-degree family history of BE or esophageal adenocarcinoma (EAC), age over 50, male sex, smoking history, central obesity, and Caucasian race. A recent meta-analysis further noted a linear increase in BE risk with each additional risk factor, which further supports the ACG's recommendation for screening men with chronic or frequent GERD symptoms who have two or more risk factors for BE and EAC. Caucasian race is included as a risk factor in BE guidelines from the ACG, AGA, and ESGE. The 2015 ASGE Guideline on Race and Ethnicity Considerations in GI Endoscopy also includes Caucasian race as a BE risk factor and cites data from a Kaiser study showing annual BE incidence rates in non-Hispanic Caucasians (39/100k), Hispanics (22/100k), Asians (16/100k), and African Americans (6/100k). As the ACG 2015 guideline notes, the Hispanic population is highly heterogeneous with some studies showing equivalent rates of BE compared to non-Hispanic Caucasians and should be taken into consideration when assessing overall risk for BE.^{106, 110, 117, 134, 143} Repeated screening after an initial negative screening exam, as well as the routine screening of women and the general population, are not recommended by the ACG.

Major GI societies recommend BE surveillance programs based on the increasing risk of progression to esophageal adenocarcinoma as dysplasia develops and the potential to reduce EAC mortality through the identification and eradication of precursor lesions. Estimated annual risks of progression are noted as follows: 0.2%-0.5% for non-dysplastic BE; 0.7% for low-grade dysplasia; 7% for high-grade dysplasia. In their 2022 update to the management of Barrett's Esophagus, the ACG recommends that the length of non-dysplastic Barrett's Esophagus be considered when determining surveillance intervals with recent systematic reviews suggesting increased risk for progression to high grade dysplasia or adenocarcinoma for segment lengths ≥ 3 cm when compared to segments < 3 cm in length.

The ACG, ASGE, and AGA all note significant interobserver variability among pathologists when making a determination of "indefinite for dysplasia" or "low-grade dysplasia," with studies showing up to 85% of low-grade dysplasia diagnoses being downgraded to after review by at least two GI pathologists. Each of these societies recommend confirmation of low-grade dysplasia by an expert or second pathologist or subsequent endoscopic biopsy under optimal acid suppression. While confirmatory pathology evaluation is considered the standard, the realities of clinical practice may limit the availability of this approach and it is expected that clinicians acting on a report of "indefinite for dysplasia" or "low-grade dysplasia" will have high confidence in the accuracy of these diagnoses when considering the risks and benefits of further intervention.

The ACG and ASGE currently recommend against routine ablative therapy for non-dysplastic BE due to the low risk of progression to EAC, and ASGE guidelines on endoscopic eradication therapy do not include indications for ablative eradication of non-dysplastic BE. The ACG and AGA recommend radiofrequency ablation as the preferred endoscopic ablative therapy for dysplastic BE, while the ASGE considers both radiofrequency and cryoablation as appropriate endoscopic eradication therapy for BE-related neoplasia. The AGA notes a lack of literature comparing alternative modalities such as photo-dynamic therapy and argon plasma coagulation head-to-head against radiofrequency ablation and the role of these treatments has yet to be determined. Current surveillance intervals following CEIM are based on recommendations from 2022 ACG guidelines on the management of Barrett's Esophagus.

Bleeding and Anemia

New or Recurrent Upper GI Bleeding

Upper endoscopy is considered medically necessary in **ANY** of the following scenarios:

- Hematemesis or "coffee-ground" emesis
- Melena
- Unexplained **rectal bleeding or positive fecal occult blood testing** when **EITHER** of the following are present:
 - Known risk factors for upper GI bleeding
 - After non-diagnostic colonoscopy

Treatment of Bleeding Lesions

Upper endoscopy is considered medically necessary for the **treatment of bleeding lesions** such as ulcers, tumors, or vascular abnormalities.

Discussion: Bleeding

Overt upper GI bleeding may present as a medical emergency and is often managed in an inpatient setting, which is outside the scope of this guideline. Signs of upper GI bleeding include hematemesis as well as blood products that have been exposed to various levels of digestion, such as "coffee ground" emesis or dark, tarry appearing melena. Conversely, lower GI sources of bleeding such as diverticulosis, angiodysplasia, colitis, and hemorrhoids often present as bright red blood per rectum or bloody/maroon-colored stools known as hematochezia. Brisk upper GI bleeding may present with hematochezia though additional symptoms of significant blood loss would be expected. Risk factors for upper GI sources of bleeding include prior upper GI bleeding, hemodynamic changes, peptic ulcer disease, coagulopathy, liver disease, and medications such as NSAIDs, anticoagulants, and anti-platelet agents. Guidelines from the ACG and ASGE recommend the use of endoscopic therapies such as

hemostatic clips, cauterization, and injection of vasoconstrictors or sclerosing agents for the treatment of bleeding lesions and have been shown to reduce the risks of further bleeding and need for surgical intervention.

Unexplained Iron Deficiency Anemia

Upper endoscopy is considered medically necessary when a GI source of occult bleeding is suspected in the following scenario:

- Serum **ferritin < 45 ng/mL**
 - In patients with known chronic inflammatory conditions, alternate measures of low iron stores may be used in place of serum ferritin, such as increased total iron-binding capacity, low serum iron level, or low transferrin saturation

Discussion: Iron Deficiency Anemia

Iron deficiency anemia can result from various GI causes such as malignancy, occult bleeding, inflammatory disease, and malabsorption. In the 2020 AGA clinical practice guidelines evaluating iron deficiency anemia, anemia is defined as a hemoglobin < 13 g/dL in men and < 12 g/dL in nonpregnant women and recommends a ferritin cutoff of 45 ng/mL for the diagnosis of iron deficiency anemia. Given the sensitivity of ferritin level to detect iron deficiency anemia, an isolated low serum ferritin may be an early indicator of occult bleeding and may warrant endoscopic evaluation regardless of hemoglobin. Ferritin may be falsely elevated in patients with underlying inflammatory conditions. In these scenarios, alternative tests that measure serum iron stores may be used to diagnosis iron deficiency anemia.

Pernicious Anemia

Upper endoscopy is considered medically necessary in patients with **established pernicious anemia** in **EITHER** of the following scenarios:

- At the time of initial diagnosis
- For new upper GI signs/symptoms

Discussion: Pernicious Anemia

Pernicious anemia results from autoantibodies that target gastric parietal cells and intrinsic factor, resulting in vitamin B12 malabsorption and deficiency. The 2015 ASGE guideline on premalignant and malignant conditions of the stomach notes a variable risk for gastric cancer and recommends endoscopic assessment at the time of diagnosis and again for the development of any new upper GI symptoms. This assessment is similar to the 2019 ESGE and 2018 British Society of Gastroenterology recommendations.

Caustic Ingestion

Upper endoscopy is considered medically necessary for patients **following caustic ingestion** in **EITHER** of the following scenarios:

- Evaluation of acute injury
- Surveillance for esophageal cancer beginning 10 years after ingestion and every 2 years thereafter

Discussion: Caustic Ingestion

Historically, ingestion of lye-based agents has been associated with an increased risk of esophageal cancer, though the ASGE notes risk following acidic exposures as well and recommends screening 10 to 20 years after injury with follow-up in 2- to 3-year intervals.

Celiac Disease

Diagnosis

Upper endoscopy is considered medically necessary in **EITHER** the following scenarios:

- Suspected celiac disease in patients with **positive IgA or IgG serologic testing**

- Suspected celiac disease in symptomatic patients, regardless of serologic testing, with **ANY** of the following risk factors:
 - Type 1 diabetes
 - First-degree relative with confirmed celiac disease
 - Documented autoimmune disorder
 - Diarrhea with clinical findings of malabsorption such as unexplained nutritional deficiencies or loss of 5% or more of usual weight

Management

Upper endoscopy is considered medically necessary for the management of established celiac disease in **EITHER** of the following scenarios:

- **Persistent or recurrent signs/symptoms** when **BOTH** of the following are met:
 - At least 1 year of documented compliance with gluten-free diet
 - Non-diagnostic serologic testing
- **Asymptomatic patients to assess healing** in order to guide pharmacologic treatment when **BOTH** of the following are met:
 - At least 2 years of documented gluten-free diet
 - Non-diagnostic serologic testing

Discussion: Celiac Disease

Celiac disease commonly leads to malabsorption through the destruction of small intestinal villi which can be confirmed with biopsy sampling during upper endoscopy. The ACG defines celiac disease as “an immune-based reaction to dietary gluten (storage protein for wheat, barley and rye) that primarily affects the small intestine in those with a genetic predisposition and resolves with exclusion of gluten from the diet.” The ACG also acknowledges that symptoms may vary from the typical diarrhea, weight loss, bloating, flatulence, and abdominal pain to the less common findings of unexplained liver function test abnormalities, iron deficiency anemia and skin disorders.

The ACG and ESGE recommend serologic testing for suspected celiac disease and note that current assays for IgA antibodies targeting tissue transglutaminase (TG2) have a sensitivity and specificity near 95%; however, IgA deficiency is more common in this population and may require the use of IgG-based serologies.

The ACG and ESGE make strong recommendations for close monitoring by a dietitian and strict, life-long adherence to a gluten-free diet (GFD), as most persistent/recurrent symptoms can be attributed to intentional or unintentional gluten consumption. The ESGE notes that villous atrophy is still present in up to 40% of patients even after one year of GFD compliance making repeat biopsy within a year unlikely to alter management. Persistent symptoms beyond this time frame with negative or low levels of celiac antibodies may warrant repeat biopsy when alternate diagnoses (such as lymphoma) or immunosuppressant treatment is being considered. The ACG notes median time of 3 years to achieve mucosal healing and suggests follow-up at least 2 years after starting GFD when assessing asymptomatic, seronegative patients for healing.

Crohn's Disease

Upper endoscopy is considered medically necessary for the **diagnosis and management of Crohn's disease** in **EITHER** of the following scenarios:

- **Suspected Crohn's disease**
 - When signs/symptoms of upper GI involvement are present
 - After non-diagnostic colonoscopy
- **Established Crohn's disease**

- Any new or persistent signs/symptoms of upper GI involvement

Discussion: Crohn's Disease

The ACG guidelines on the diagnosis and management of Crohn's disease and ulcerative colitis note that ileocolonoscopy with biopsy is the initial test of choice for diagnosis, and that upper endoscopy should only be performed to evaluate Crohn's disease when upper GI signs or symptoms are present or when colonoscopy is non-diagnostic. The 2015 ASGE guidelines similarly recommend against routine EGD in adult patients suspected of having Crohn's disease unless colonoscopy is non-diagnostic.

Duodenal Masses

Duodenal Carcinoma

Upper endoscopy is considered medically necessary for the **management of established duodenal carcinoma**.

Ampullary and Non-ampullary Adenomas (not associated with familial polyposis syndromes)

Upper endoscopy is considered medically necessary for the **management of established ampullary and non-ampullary duodenal adenomas**.

Discussion: Duodenal Masses

The major duodenal papilla (also known as the ampulla of Vater) are located in the second portion of the duodenum where the pancreatic and common bile duct converge and empty into the small intestine. Ampullary and non-ampullary adenomas may not be distinguishable from malignancy, and the ASGE and NCCN recommend surveillance of both resected and non-resected adenomas, though optimal intervals have not been established.

Dyspepsia

Upper endoscopy is considered medically necessary for patients with **predominant epigastric discomfort for 4 weeks or greater** in **ANY** of the following scenarios:

- Initial evaluation of dyspepsia in the **presence of alarm features**
- Initial evaluation of patients **aged 55 years or older**
- For patients aged 54 years or younger, when dyspepsia persists after **BOTH** of the following are met:
 - *H. pylori* testing/treatment
 - 4 weeks of treatment with PPI

Discussion: Dyspepsia

The 2017 ACG guideline on The Management of Dyspepsia considers a clinically relevant definition of dyspepsia to be "predominant epigastric pain lasting at least 1 month." The risk of upper GI malignancy is predominantly related to age and is a common concern in patients presenting with undifferentiated dyspepsia. Age cutoffs between 50 and 60 for early endoscopy have been recommended by the ACG, the ASGE, and the American Gastroenterological Association (AGA).

In the absence of an indication for early endoscopy, the ACG, AGA and ASGE all recommend a strategy of non-invasive *H. pylori* testing/treatment as well as an empiric trial of acid suppression in this population.^{52, 72, 132} The ACG's 2017 guideline makes a strong recommendation for both a testing/treatment *H. pylori* strategy as well as empiric PPI trial for dyspeptic patients under 60, noting that given equal costs of currently available H2RA and PPI, PPI should be favored given multiple trials that showed a significant effect in favor of PPI use. The ASGE and AGA similarly recommend a PPI course of at least 4 weeks over alternate acid suppressing regimens. PPI treatment should be withheld for 1 to 2 weeks prior to either invasive or non-invasive *H. pylori* testing to maximize test sensitivity.

Eosinophilic Esophagitis

Upper endoscopy is considered medically necessary for the **management of established eosinophilic esophagitis** in **ANY** of the following scenarios:

- Evaluation of alarm features
- Reassessment when required **to direct a change in therapy or perform dilation after 8-week course of ANY** of the following:
 - Dupilumab
 - PPI
 - Topical corticosteroids
 - Elimination diet
- Following initial dilation, repeat dilation may be performed until adequate resolution of stricture

Discussion: Eosinophilic Esophagitis

Eosinophilic esophagitis (EoE) is a clinicopathologic disorder characterized by symptoms of esophageal dysfunction and eosinophil-predominant inflammation confirmed on biopsy that is typically performed during the evaluation of GERD or dysphagia. Following diagnosis, the AGA and a 2018 international consortium recommend that PPIs, swallowed steroids and dietary elimination all be considered as initial treatments, typically in 6- to 12-week regimens. Esophageal inflammation and fibrosis can lead to strictures and a “narrow-caliber esophagus,” however in the absence of a critical stricture or food impaction, the ACG recommends dilation only after a failed response to medical or dietary therapy which is also supported by recent AGA guidelines. A 2016 randomized controlled trial by Kavitt, et al. showed equivalent improvements in dysphagia scores for patients with biopsy-confirmed EoE following treatment with either dilation or dual medical therapy of swallowed steroids plus PPI at 30 and 60 days. The ACG emphasizes the chronic nature of EoE and likelihood of symptoms to recur after treatment is stopped, therefore repeat endoscopic evaluation should be limited to the development of new alarm features or when required to direct a change in therapy.

Esophageal Malignancies

Upper endoscopy is considered medically necessary for the **management of biopsy-confirmed esophageal cancer** in **ANY** of the following scenarios:

- Endoscopic lesion **resection**
- Signs or symptoms of **recurrent or progressive disease**
- Following resection without esophagectomy of **squamous cell cancer to direct management decisions**
- Management of **T1a Esophageal Adenocarcinoma** (EAC, or Intramucosal Cancer IMC) in **EITHER** of the following:
 - **Endoscopic ablative treatment with radiofrequency ablation or cryoablation** may be performed and repeated until the patient achieves complete eradication of intestinal metaplasia (CEIM)
 - **Surveillance** endoscopy following confirmed eradication, every 3 months for the first year, every 6 months for the second year, and then annually
- Management of T1b Esophageal Adenocarcinoma in **EITHER** of the following:
 - **Endoscopic ablative treatment with radiofrequency ablation or cryoablation** may be performed and repeated until the patient achieves complete eradication of intestinal metaplasia (CEIM)
 - **Surveillance** endoscopy following confirmed eradication, every 3 months for the first year, every 4 months for the second year, and then annually

Discussion: Esophageal Malignancies

For patients with early EAC, the potential for curative endoscopic treatment depends on depth of invasion. Currently, the ACG strongly recommends ablative therapy for T1a EAC, also known as intramucosal cancer (IMC). The ASGE similarly recommends ablative therapy over surveillance or esophagectomy for IMC. Since stage T1b EAC has a much higher risk of lymph node progression than T1a, the ACG recommends multidisciplinary surgical oncology evaluation of any patient with stage T1b EAC being considered for endoscopic therapy to assess surgical candidacy and histopathology characteristics. The ACG and NCCN note limited invasion into the sm1 region of the submucosa, well-differentiated tumors and lack of lymphovascular invasion as factors that may increase curative success of endoscopic therapy. When considering palliative therapies for non-curative obstructing lesions, the ASGE and NCCN recommend tumor ablation or debulking, self-expandable metal stents and dilation therapies.

The ACG and AGA recommend radiofrequency ablation as the preferred endoscopic ablative therapy for dysplastic BE, while the ASGE considers both radiofrequency and cryoablation as appropriate endoscopic eradication therapy for BE-related neoplasia. The AGA notes a lack of literature comparing alternative modalities such as photo-dynamic therapy and argon plasma coagulation head-to-head against radiofrequency ablation, and the role of these treatments has yet to be determined.

While noting an association between upper airway squamous cell cancer and esophageal malignancies, the ASGE recommends against routine endoscopic screening due to lack of evidence of improved outcomes.

Esophageal Varices

Upper endoscopy is considered medically necessary for **patients with cirrhosis or portal hypertension in ANY** of the following scenarios:

- **Initial screening** for esophageal varices after diagnosis of cirrhosis or portal hypertension
- Surveillance of non-bleeding varices in patients **not treated with prophylactic beta-blockers** in the following intervals:
 - **No varices**: Every 2 years
 - **Small varices** (< 5 mm): Annually
 - Any **varices with high-risk stigmata** (such as ≥ 5 mm or red wale markings): Annually
 - **Decompensated cirrhosis or continued alcohol use**: Annually
- **Treatment** of bleeding or non-bleeding esophageal varices with **EITHER** of the following:
 - Endoscopic ligation, **repeated until eradication**
 - **Sclerotherapy if ligation not technically feasible**, repeated until eradication
- **Following eradication** with ligation or sclerotherapy:
 - Initial endoscopy after 3 months
 - Continued surveillance every 6 months

Discussion: Esophageal Varices

The fibrotic and vascular changes that occur during progressive liver injury increase the resistance to blood flow and lead to elevated blood pressure throughout the portal system known as portal hypertension. Clinical signs of portal hypertension include ascites, spider nevi, visible collateral vessels such as caput medusae, thrombocytopenia, or visible collateral vessels on imaging studies. Portal hypertension promotes the development of collateral veins and specifically esophageal varices (EV). The ACG notes varices are present in approximately 50% of patients with cirrhosis and develop at a rate of 8% per year. Variceal size is the main predictor of hemorrhage and used to determine treatment options for the primary prevention of bleeding.

The ACG, ASGE, and American Association for the Study of Liver Disease (AASLD) recommend screening for EV at the time cirrhosis or portal hypertension is diagnosed. Two methods of primary prophylaxis against variceal bleeding are recommended by the ACG, ASGE and AASLD: EGD surveillance with the intent of ligating high-risk

varices and treatment with non-selective beta-blockers (such as Propranolol or Nadolol) or Carvedilol. The ACG, ASGE and AASLD do not recommend combined treatment with beta-blockers plus EGD surveillance for the management of varices that have not bled.^{33, 34, 127} However, beta-blocker intolerance is common and may result in switching to an EGD-based strategy. Following ligation or sclerotherapy for bleeding varices, the ASGE and AASLD recommend surveillance every 3 to 6 months. Signs of decompensated liver disease include hepatic encephalopathy, ascites and variceal hemorrhage which is often life threatening and may require resuscitative measures.

Gastric Intestinal Metaplasia (GIM)

GIM without Dysplasia

Upper endoscopy is considered medically necessary **following *H. pylori* testing/treatment** in **ANY** of the following scenarios:

- Initial **follow-up at 1 year for mapping biopsies** if not performed at the time of diagnosis
- Surveillance endoscopy **every 3 years** when **ANY** of the following risk factors are present:
 - Patients of racial or ethnic groups known to be at higher risk for gastric cancer
 - First-degree relative with history of gastric cancer
 - Incomplete GIM
 - Extensive GIM

GIM with Low-grade Dysplasia

Upper endoscopy is considered medically necessary in **ANY** of the following scenarios:

- Endoscopic lesion resection
- Repeated endoscopy for **mapping biopsies** if not performed at the time of diagnosis
- Surveillance endoscopy **following *H. pylori* testing/treatment** at the following intervals:
 - **Annually** until negative for dysplasia and no visible lesions, **then every 3 years**

GIM with High-grade Dysplasia

Upper endoscopy is considered medically necessary in **EITHER** of the following scenarios:

- Endoscopic lesion resection
- Surveillance endoscopy **following *H. pylori* testing/treatment** at the following intervals:
 - Every 6 months, 12 months, then annually for 3 years, and then every 3 years

Discussion: Gastric Intestinal Metaplasia

Gastric intestinal metaplasia (GIM) is often found incidentally during endoscopy, has been associated with gastric cancer and is believed to be a precursor lesion prior to the development of dysplasia. The most recent AGA guidelines on GIM strongly recommend testing and eradication of *H. pylori* in all patients with GIM due to its carcinogenic effects and recommend against the routine surveillance of GIM. The AGA, ASGE, and ESGE note that surveillance may be beneficial in a subset of individuals with additional risk factors for gastric cancer, some of which can only be determined by performing “mapping” biopsies taken from various areas of the stomach including the gastric body, antrum, and incisura.^{41, 94, 122} The ASGE Guideline on Race and Ethnicity Considerations for Endoscopy specifies that the incidence of gastric cancer in the U.S. is significantly higher among Asian Americans, African Americans, Hispanics and Native Americans compared to Caucasians as well as immigrants from East Asia, South America, and Russia. Optimal surveillance intervals in patients with risk factors or dysplasia have not been established; however, the AGA suggests 3- to 5-year follow-up. The NCCN recommends close follow-up of high-grade dysplasia following resection, and the ASGE recommends general surveillance be discontinued after two studies have been negative for dysplasia.

Gastric Malignancies

Adenocarcinoma

Upper endoscopy is considered medically necessary for **established gastric adenocarcinoma or carcinoma in situ** in **ANY** of the following scenarios:

- For endoscopic lesion resection
- For new signs/symptoms of recurrence/progression
- For **carcinoma in situ** treated with endoscopic resection:
 - Surveillance endoscopy at 6 months, 12 months, then annually for 3 years
- For **invasive gastric adenocarcinoma** treated with endoscopic resection:
 - Surveillance endoscopy at 6 months, 12 months, then annually for 5 years

Discussion: Gastric Adenocarcinoma

Adenocarcinoma makes up 95% of gastric cancers and overall incidence rates in the U.S. are decreasing. When found in early stages, gastric cancer may be treatable with curative endoscopic resection, and follow-up surveillance is recommended by the NCCN. Gastric outlet obstruction may occur in patients with incurable disease for which the NCCN recommends the use of resection, stenting, and feeding/drainage tubes when necessary for palliation.

The joint ACG and ASGE publication on EGD quality indicators notes that endoscopic surveillance for malignancy is generally not required in patients with gastric atrophy, pernicious anemia, or prior gastric operations for benign disease.

Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Upper endoscopy is considered medically necessary for **established MALT** in **ANY** of the following scenarios:

- For endoscopic lesion resection
- For new signs/symptoms of recurrence/progression
- Following **treatment with chemotherapy, immunotherapy, or radiotherapy** to direct further management
- Following ***H. pylori* treatment alone** at the following intervals:
 - Surveillance endoscopy every 3 months for the first 2 years, then every 6 months until 5 years

Discussion: MALT Lymphoma

Mucosa-associated lymphoid tissue (MALT) lymphoma is a low-grade B-cell lymphoma that occurs in the lymphoid tissue that lies within the mucosa of the stomach, lung, small bowel, and other organs. *H. pylori* infection is almost always present in patients diagnosed with gastric MALT and chronic inflammatory changes are believed to play a causative role. Eradication of *H. pylori* alone will lead to clinical remission in up to 95% of patients with localized MALT lymphoma; however, continued surveillance is recommended by the NCCN with follow-up endoscopic biopsy recommended by the ASGE. Patients with advanced, disseminated disease may be treated with chemotherapy, immunotherapy and/or radiation therapy and post-treatment endoscopic evaluation is recommended by the NCCN.

Upper GI Neuroendocrine Tumors (NET)

Upper endoscopy is considered medically necessary for **established upper GI neuroendocrine tumors** in **ANY** of the following scenarios:

- For endoscopic lesion resection
- For new signs/symptoms of recurrence/progression
- For **type 1 and 2 gastric NET** at the following intervals:

- Surveillance endoscopy annually
- For **type 3 gastric NET** not treated with surgical resection, when needed to direct further management
- For **duodenal NET**: Follow-up endoscopy when needed to direct further management

Discussion: Upper GI Neuroendocrine Tumors

Upper GI neuroendocrine tumors (NET) may also be referred to as carcinoid tumors and are categorized into three types. Type 1 is the most common and typically has a benign clinical course. Type 2 is associated with Zollinger-Ellison and multiple endocrine neoplasia syndromes, typically occurring in the setting of a gastrinoma and has a 10%-30% rate of lymph node metastases at the time of diagnosis. Type 3 tumors occur sporadically, are typically diagnosed at advanced stages with poor prognoses and should be considered for surgical resection. ASGE guidelines suggest surveillance after resection and propose 1- to 2-year intervals while noting that optimal surveillance frequency is unknown. NCCN recommends endoscopic follow-up every 2 to 3 years for type 1 gastric NET, and notes that follow-up endoscopy should be considered for type 2 gastric NET.

Gastrointestinal Stromal Tumors (GIST)

Upper endoscopy is considered medically necessary for **established GI stromal tumors (GIST)** in **ANY** of the following scenarios:

- For endoscopic lesion resection
- For new signs/symptoms of recurrence/progression
- Surveillance endoscopy for GIST not treated with resection **annually**

Discussion: GI Stromal Tumors

Gastrointestinal stromal tumors (GIST) are a form of soft tissue sarcoma that develop below the epithelial surface and are typically identified on imaging followed by confirmatory endoscopic ultrasound-guided tissue diagnosis. Asymptomatic gastric GIST ≤ 2 cm with low-risk features are generally considered benign and candidates for surveillance with endoscopic ultrasound, whereas symptomatic tumors or those > 2 cm are typically resected. The NCCN recommends advanced imaging modalities for continued surveillance of metastatic tumors or those treated with resection rather than endoscopic surveillance.

Gastric Polyps

Hyperplastic Polyps

Upper endoscopy is considered medically necessary for **established hyperplastic polyps following *H. pylori* testing/treatment** in the following scenario:

- Surveillance endoscopy **annually** until negative for polyp or dysplasia

Discussion: Hyperplastic Polyps

Hyperplastic polyps may occur in the presence of *H. pylori* infection and are a form of gastric epithelial polyp often found incidentally during endoscopy. Unlike sporadic fundic gland polyps which are not associated with increased cancer risk unless part of an underlying familial polyposis syndrome, the ASGE notes that dysplasia and focal cancer have been found in 5%-19% of hyperplastic polyps, with polyps > 1 cm or pedunculated morphology at highest risk.

Adenomatous Polyps

Upper endoscopy is considered medically necessary for **established adenomatous polyps** in **ANY** of the following scenarios:

- For endoscopic lesion resection
- For polyps with **no dysplasia or low-grade dysplasia**, surveillance endoscopy at the following intervals:

- 1 year following resection and then every 3 years
- For polyps with **high-grade dysplasia**, surveillance endoscopy at the following intervals:
 - At 6 months, 12 months, then annually for 3 years, then every 3 years

Discussion: Adenomatous Polyps

Adenomatous polyps are considered a precancerous lesion and require further surveillance following resection. The ASGE recommends follow-up at one year and continued surveillance every 3 to 5 years. Additional publications have advocated for shorter initial interval follow-up for dysplastic adenomas before continuing with surveillance every 3 to 5 years.

Gastroesophageal Reflux Disease (GERD)

Upper endoscopy is considered medically necessary in **ANY** of the following scenarios:

- GERD symptoms in the presence of **alarm features**
- Persistent GERD symptoms **following an 8-week course of PPI treatment**
- Follow-up evaluation for patients noted to have **Los Angeles class C or D erosive esophagitis** on initial endoscopy following a subsequent 8-week course of PPI treatment

Discussion: GERD

GERD is commonly described as the reflux of stomach contents into the esophagus or beyond causing symptoms of heartburn or regurgitation. The ACG, AGA, and ASGE have all endorsed empiric trials of antisecretory treatment for uncomplicated GERD symptoms, with the ACG and AGA both recommending use of PPIs over H2Ras and the ACG further specifying an 8-week duration of treatment prior to considering endoscopy.^{52, 55, 129}

The presence of erosive esophagitis may prevent adequate biopsy sampling or obscure histopathologic detection of Barrett's esophagus on initial endoscopy. The Los Angeles classification system is used by the ACG, AGA, and ASGE to report esophagitis severity on a scale from A to D, and the ACG and ASGE both recommend follow-up endoscopy after a minimum 8-week PPI treatment course for severe, Grade C and D erosive esophagitis.

Extra-esophageal symptoms, such as chronic cough, laryngitis, and asthma, are frequently attributed to GERD; however, the ACG, AGA, and ASGE recommend against routine EGD for evaluation of these symptoms in the absence of typical GERD symptoms, as the results are unlikely to change management and the likelihood of identifying erosive disease is low.

Genetic-Familial Conditions Associated with Upper GI Malignancies

Adenomatous Polyposis Syndromes

Upper endoscopy is considered medically necessary for **patients with confirmed adenomatous polyposis syndromes** for **ANY** of the following scenarios:

- For new upper GI signs/symptoms
- For **Familial Adenomatous Polyposis (FAP)** or **Attenuated-Familial Adenomatous Polyposis (AFAP)**, surveillance endoscopy at the following intervals:
 - Beginning at age 20
 - Subsequent surveillance of duodenal polyps per Spigelman stage ([Table 1](#))
 - Subsequent surveillance of gastric polyps per NCCN recommendation schedule ([Table 2](#))
- For **MUTYH-Associated Polyposis (MAP)**, surveillance endoscopy at the following intervals:
 - Beginning at age 30 with subsequent surveillance per Spigelman stage ([Table 1](#)) for duodenal polyps

Table 1. Endoscopic duodenal surveillance based on modified Spigelman score and stage in FAP

CRITERIA	SCORE			
	0 Points	1 Point	2 Points	3 Points
Polyp number	0	1–4	5–20	> 20
Polyp size, mm	No polyps	1–4	5–10	> 10
Histology	No adenomas	Tubular adenomas	Tubulovillous adenoma	Villous adenoma
Dysplasia	No dysplasia	Low grade	—	High grade

SPIGELMAN SCORE	SPIGELMAN STAGE	SURVEILLANCE	
0 points	0	Repeat endoscopy	Every 3–5 years
1–4 points	I	Repeat endoscopy	Every 2–3 years
5–6 points	II	Repeat endoscopy	Every 1–2 years
7–8 points	III	Repeat endoscopy	Every 6–12 months
9–12 points	IV	Expert surveillance	Every 3–6 months

Source: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High-Risk Assessment: Colorectal. Version 1.2023 Familial Adenomatous Polyposis.

Table 2. Gastric polyp characteristics and recommended surveillance intervals

Gastric Polyp Characteristics and Recommended Surveillance Intervals:^{9,h}

Histology	Size	Dysplasia	Surveillance Interval ⁱ
Fundic gland polyps (FGP)	<1 cm	None or low grade	3 y
	≥1 cm	None or low grade	1 year (6 mo if piecemeal resection or unable to remove all large polyps in a single procedure)
	Any size	High grade*	3–6 mo and consider endoscopic management at an expert center or surgical evaluation
Gastric adenomas (GA) or Pyloric gland adenomas (PGA)	<1 cm	—	1 y
	≥1 cm	—	1 year (6 mo if piecemeal resection or unable to remove all large polyps in a single procedure)
	Any size	High grade*	3–6 mo and consider endoscopic management at an expert center or surgical evaluation
Any proximal polypoid mounds – FGP, PGA, GA	N/A	None or low grade	3–6 mo
		High grade*	Referral for endoscopic management at expert center and surgical evaluation
Intramucosal or invasive adenocarcinoma	N/A	N/A	Surgical evaluation for possible gastrectomy

* Multifocal high-grade dysplasia should prompt referral for surgical evaluation for possible gastrectomy.

- If partial gastrectomy is performed for antral neoplasia, then continue surveillance of the remaining stomach as above.
- Intervals for upper endoscopy surveillance should be determined based on gastric and/or duodenal findings and whichever requires more frequent surveillance should be applied.

Source: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High-Risk Assessment: Colorectal. Version 4.2024 Familial Adenomatous Polyposis.

Discussion: Adenomatous Polyposis Syndromes

The ACG describes three hereditary syndromes associated with early onset colorectal and upper GI adenomas related to mutations in the *APC* tumor suppressor genes and *MUTYH* DNA repair genes: familial adenomatous polyposis (FAP), attenuated-familial adenomatous polyposis (AFAP) and *MUTYH*-associated polyposis (MAP). Screening strategies for upper GI tract malignancies include an initial endoscopy between 25 and 30 years of age for FAP/AFAP and 30 years of age for MAP with subsequent follow-up determined by the Spigelman stage that incorporates the number, size, and histopathologic features of any noted duodenal polyps. Patients with Spigelman stage IV have a 36% risk of duodenal cancer within 10 years.

Lynch Syndrome (Hereditary Non-Polyposis Colon Cancer)

Upper endoscopy is considered medically necessary for **patients with confirmed Lynch syndrome** in **ANY** of the following scenarios:

- For new upper GI signs/symptoms
- Screening endoscopy beginning at age 30 with follow-up every 2 years in patients with **ANY** of the following risk factors:
 - Patients with *MLH1*, *MSH2*, *MSH6*, *PMS2*, or *EPCAM* mutations
 - First-degree relative with history of upper GI cancer
 - Patients of racial or ethnic groups known to be at higher risk for gastric cancer

Discussion: Lynch Syndrome

Lynch syndrome is caused by autosomal dominant mutations in DNA mismatch repair genes (*MLH1*, *MSH2*, *MSH6* and *PMS2*) or the associated *EPCAM* gene and is the most common cause of inherited colorectal cancer. The 2014 ACG guidelines and 2024 NCCN guidelines on Lynch syndrome suggest screening endoscopy for high-risk patients beginning at age 30 to 35 years. A recent prospective cohort study of over 51,000 individuals with genetic mutations for Lynch syndrome reported significant associations between patient age, first-degree relatives with gastric cancer, and mutations in *MLH1* and *MSH2* genes with the development of gastric cancer. The 2024 NCCN guidelines include recommendations for surveillance of *MSH6* mutations as well as surveillance every 2 to 4 years. NCCN also suggests surveillance of patients with Lynch syndrome who lack the listed genetic mutations when specific risk factors for upper gastrointestinal cancers are present.

Peutz-Jeghers Syndrome

Upper endoscopy is considered medically necessary for **patients with confirmed Peutz-Jeghers syndrome** in **ANY** of the following scenarios:

- Initial screening endoscopy
- For new upper GI signs/symptoms
- Surveillance endoscopy every 2 years

Discussion: Peutz-Jeghers Syndrome

Peutz-Jeghers syndrome (PJS) results from an autosomal dominant mutation and causes polyps throughout the GI tract and mucocutaneous pigmentation with a high risk of GI and extraintestinal cancers.

Juvenile Polyposis Syndrome

Upper endoscopy is considered medically necessary for **patients with confirmed juvenile polyposis syndrome** in **ANY** of the following scenarios:

- Initial screening endoscopy
- For new upper GI signs/symptoms
- Surveillance endoscopy annually

Discussion: Juvenile Polyposis Syndrome

Juvenile polyposis syndrome (JPS) results from an autosomal dominant mutation with an average age of diagnosis of 18.5 years. JPS is characterized by the early development of polyps throughout the GI tract and an increased risk for upper and lower GI cancers.

Li-Fraumeni Syndrome

Upper endoscopy is considered medically necessary for **patients with confirmed Li-Fraumeni syndrome** in **ANY** of the following scenarios:

- Screening endoscopy at age 25 (or 5 years before first known familial colon cancer diagnosis if earlier)

- For new upper GI signs/symptoms
- Surveillance endoscopy every 2 years

Discussion: Li-Fraumeni Syndrome

Li-Fraumeni syndrome is a rare hereditary cancer syndrome related to mutations in *TP53* gene pathway with an overall lifetime risk of cancer of nearly 100%. The NCCN recommends screening/surveillance upper endoscopy and colonoscopy beginning at age 25 (or 5 years before the first known familial colon cancer diagnosis) and continued every 2 to 5 years.

Hereditary Diffuse Gastric Cancer

Upper endoscopy is considered medically necessary for patients with **confirmed genetic testing for Hereditary Diffuse Gastric Cancer** in **EITHER** of the following scenarios:

- Preoperative evaluation for prophylactic gastrectomy
- Surveillance endoscopy annually for patients considering delayed gastrectomy

Discussion: Hereditary Diffuse Gastric Cancer

Hereditary diffuse gastric cancer results from an autosomal dominant mutation in the *CDH1* gene with an average age of gastric cancer diagnosis at 37 years. Given the extremely high risk of gastric cancer, the standard of care is prophylactic gastrectomy at the time of diagnosis, which may require a preoperative endoscopy for surgical planning. NCCN cites emerging data that patients under surveillance rarely develop greater than stage pT1a gastric carcinoma and at least annual upper endoscopy surveillance is required to support delayed gastrectomy.

Tylosis

Upper endoscopy is considered medically necessary for **patients with confirmed Tylosis** in **ANY** of the following scenarios:

- Screening endoscopy at time of diagnosis
- For new upper GI signs/symptoms
- Surveillance endoscopy annually

Discussion: Tylosis

Tylosis is a very rare condition resulting from an autosomal dominant mutation in the *RHBDF2* gene which increases the risk of squamous cell esophageal cancer. The NCCN recommends routine endoscopic screening beginning after age 20, while the ASGE recommends screening at age 30 or the age of onset with follow-up in 1- to 3-year intervals.

Helicobacter pylori

Upper endoscopy is considered medically necessary for the following scenario:

- Gastric biopsy to perform *H. pylori* antibiotic susceptibility testing using culture or genetic-based methods for patients who have refractory infection after completion of guideline-directed therapy.

Discussion: Helicobacter pylori

Helicobacter pylori (*H. pylori*) is a widespread bacterial pathogen with markedly variable prevalence across geographic regions and cohorts. Given the causal linkage between *H. pylori* and peptic ulcer disease as well as its classification by the World Health Organization as a carcinogen, the 2024 ACG guidelines on *H. pylori* treatment recommend *H. pylori* testing in patients with peptic ulcer disease, mucosa-associated lymphoid tissue (MALT) lymphoma, early gastric cancer, dyspepsia and several other scenarios with increased risk for gastric cancer. The ACG similarly makes a strong recommendation to treat all patients who test positive for *H. pylori*, regardless of the initial indication for testing. Several treatment regimens exist and are typically comprised of 2 to 3 antibiotics along with a PPI for a duration of 3 to 14 days. When testing to confirm eradication, the ACG recommends non-invasive testing at least 4 weeks after therapy completion. Given the known risks of untreated

H. pylori infection and strong literature base to support eradication, it is assumed that *H. pylori* testing and treatment for positive results (referred to as “*H. pylori* testing/treatment”) will be performed when appropriate, even if not specifically included in the guideline below. Given the widespread availability of non-invasive testing such as the urea-breath test and stool antigens, confirmation of *H. pylori* eradication is not considered an independent indication for upper endoscopy; however, endoscopy may be indicated for cases of refractory *H. pylori* infection to determine antibiotic susceptibility and guide subsequent treatment decisions.

American College of Gastroenterology Clinical Practice Guideline for Treatment of *H. pylori* Infection

ACG Clinical Practice Guideline

Treatment of <i>H. pylori</i> Infection in North America				
	Treatment Naïve	Treatment-Experienced (Salvage)		Penicillin Allergy
Regimen		Empiric	Proven antibiotic sensitivity	
Optimized Bismuth Quadruple	  	 	 	   *
Rifabutin Triple	 	 	 	
Vonoprazan Dual	 			
Vonoprazan Triple			 	
Levofloxacin Triple			 	

   Recommended

  Suggested

 May be considered when other treatments are not options

* When Bismuth Quadruple Therapy not an option, consider referral for formal penicillin allergy testing and/or desensitization

Table 5. Recommended regimens for treatment-naïve patients with *H. pylori* infection

Regimen	Drugs (doses)	Dosing frequency	FDA approval	Recommendation
Optimized bismuth quadruple ^a	PPI (standard dose) ^b Bismuth subcitrate (120–300 mg) or subsalicylate (300 mg) ^d Tetracycline (500 mg) ^e Metronidazole (500 mg)	b.i.d. q.i.d. q.i.d. t.i.d. or q.i.d.	No ^c	Strong (moderate quality of evidence)
Rifabutin triple (Talicia) ^f	Omeprazole (10 mg) ^b Amoxicillin (250 mg) Rifabutin (12.5 mg)	4 capsules t.i.d.	Yes	Conditional (low quality of evidence)
PCAB dual (Voquezna DualPak) ^g	Vonoprazan (20 mg) Amoxicillin (1,000 mg)	b.i.d. t.i.d.	Yes	Conditional (moderate quality of evidence)
PCAB triple (Voquezna TriplePak) ^h	Vonoprazan (20 mg) Clarithromycin (500 mg) Amoxicillin (1,000 mg)	b.i.d.	Yes	Conditional (moderate quality of evidence)

Chey WD, Leontiadis GI, Howden CW, et al. ACG Clinical Guideline: Treatment of *Helicobacter pylori* Infection. *Am J Gastroenterol.* 2017;112(2):212-39.

Imaging Abnormalities

Upper endoscopy is considered medically necessary for the **diagnosis of lesions identified on other imaging that have not previously been evaluated by endoscopy** in **ANY** of the following scenarios

- Suspected neoplastic lesion
- Gastric or esophageal ulcer
- Upper tract stricture or obstruction

Discussion: Imaging Abnormalities

Imaging abnormalities are common among both symptomatic and asymptomatic patients and may be incidentally noted or found during a diagnostic workup. Endoscopic evaluation is appropriate to confirm a suspected diagnosis through direct visualization or biopsy collection when expected to further direct management decisions. Many imaging findings do not require further evaluation either due to the diagnostic certainty of the imaging itself or due to the very low risk of associated pathology. While a small portion of gastric ulcers may represent underlying malignancy, duodenal ulcers are extremely unlikely to be malignant and routine biopsy and follow-up are not recommended by the ASGE. The joint publication on EGD quality indicators by the ACG and ASGE lists the following as findings that do not warrant endoscopic evaluation:

- Asymptomatic or uncomplicated sliding hiatal hernias
- Uncomplicated duodenal ulcers that have responded to therapy
- Deformed duodenal bulbs when symptoms are absent or respond adequately to ulcer.

Peptic Ulcer Disease (PUD)

Upper endoscopy is considered medically necessary in **ANY** of the following scenarios:

- Gastric or esophageal ulcer seen on other imaging that has not previously been evaluated by endoscopy
- Evaluation of alarm features
- Follow up of known PUD after an **8-week course of PPI treatment and *H. pylori* testing/treatment** in **ANY** of the following scenarios:
 - Persistent symptoms
 - Follow up of ulcers that appeared suspicious for malignancy due to **ANY** of the following:
 - Associated mass lesion
 - Elevated or irregular borders
 - Abnormal adjacent mucosal folds
 - Size: Gastric ulcers > 3 cm or duodenal ulcers > 2 cm
 - Repeat surveillance **after 8-week PPI treatment intervals** for persistent unexplained ulcers until healing documented

Discussion: Peptic Ulcer Disease

Peptic ulcers are typically diagnosed during endoscopy performed for symptoms such as dyspepsia and may be located in the gastric or duodenal walls. In the absence of alarm features, the ASGE notes that the purpose of upper endoscopy in patients with uncomplicated peptic ulcer disease is to confirm a diagnosis and rule out malignancy. The ASGE recommends against routine evaluation or surveillance of duodenal ulcers seen on radiologic imaging or those that respond to treatment due to a very low risk of underlying malignancy. Gastric ulcers, however, should generally be biopsied to rule out underlying malignancy and may warrant follow-up for persistent symptoms or suspicious features following 8 to 12 weeks of optimal antisecretory therapy. PPI treatment has repeatedly demonstrated superior ulcer healing compared to H2RA and the ACG 2017 guidelines

on *H. pylori* management make a strong recommendation for testing and treatment for all patients with active peptic ulcer disease.

Postoperative/Post-procedure Complications

Upper endoscopy is considered medically necessary for **the endoscopic diagnosis and management of post-surgical or post-procedural complications**.

Preoperative Evaluation of Asymptomatic Patients prior to Bariatric Surgery

Upper endoscopy is considered medically necessary for **ANY** of the following scenarios:

- Suspected esophagitis or Barrett's esophagus **prior to sleeve gastrectomy**
- Suspected gastric lesions **prior to Roux-en-Y gastrojejunal bypass (RYGB) following *H. pylori* testing/treatment** in **ANY** of the following high-risk patients:
 - Age 55 years or older
 - Positive *H. pylori* testing
 - First-degree relative with history of gastric cancer
 - Patients of racial or ethnic groups known to be at higher risk for gastric cancer

Discussion: Preoperative Endoscopy for Bariatric Surgery

The likelihood of asymptomatic screening endoscopy to alter bariatric surgery management is highly dependent on patient- and procedure-specific risk factors. Esophagitis is considered a relative contraindication for sleeve gastrectomy due to the possible risk of worsening GERD and development of Barrett's esophagus after this procedure. Conversely, Roux-en-Y gastrojejunal bypass (RYGB) surgery creates an "excluded stomach" and is typically avoided in patients with increased risk for future gastric malignancy.

The 2015 ASGE guideline on The Role of Endoscopy in the Bariatric Surgery Patient suggests that preoperative endoscopy be considered on an individual basis based on the type of bariatric procedure being performed and notes that an esophagram may be a useful alternative. A 2019 multispecialty clinical practice guideline for the perioperative support of patients undergoing bariatric procedures, which included the American Society for Metabolic and Bariatric Surgery, includes a Grade D (primarily based on expert opinion) statement that "the use of preoperative endoscopy may be considered in all patients being evaluated for sleeve gastrectomy."

Exclusions

Indications and procedures other than those addressed in this guideline are considered **not medically necessary** including, but not limited to, the following:

- Endoscopic ultrasound
- Placement of pH probe

References

1. Abdalla M, Dhanekula R, Greenspan M, et al. Dysplasia detection rate of confirmatory EGD in nondysplastic Barrett's esophagus. *Dis Esophagus*. 2014;27(6):505-10.
2. Ackroyd R, Tam W, Schoeman M, et al. Prospective randomized controlled trial of argon plasma coagulation ablation vs. endoscopic surveillance of patients with Barrett's esophagus after antireflux surgery. *Gastrointest Endosc*. 2004;59(1):1-7.
3. Akbari M, Tabrizi R, Kardeh S, et al. Gastric cancer in patients with gastric atrophy and intestinal metaplasia: A systematic review and meta-analysis. *PloS One*. 2019;14(7):e0219865.
4. Altayar O, Davitkov P, Shah SC, et al. AGA Technical Review on Gastric Intestinal Metaplasia-Epidemiology and Risk Factors. *Gastroenterology*. 2020;158(3):732-44.e16.

5. Al-Toma A, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. *United European Gastroenterol J*. 2019;7(5):583-613.
6. Alves JR, Graffunder FP, Rech JVT, et al. Diagnosis, Treatment and Follow-up of Barrett's Esophagus: A Systematic Review. *Arq Gastroenterol*. 2020;57(3):289-95.
7. ASGE STANDARDS OF PRACTICE COMMITTEE, Coelho-Prabhu N, Forbes N, et al. Adverse events associated with EGD and EGD-related techniques. *Gastrointest Endosc*. 2022;96(3):389-401.e1.
8. Azagury D, Dumonceau JM, Morel P, et al. Preoperative work-up in asymptomatic patients undergoing Roux-en-Y gastric bypass: is endoscopy mandatory? *Obes Surg*. 2006;16(10):1304-11.
9. Bacha D, Walha M, Ben Slama S, et al. Chronic gastritis classifications. *La Tunisie Medicale*. 2018;96(7):405-10.
10. Banks M, Graham D, Jansen M, et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. *Gut*. 2019;68(9):1545-75.
11. Bennett S, Gostimir M, Shorr R, et al. The role of routine preoperative upper endoscopy in bariatric surgery: a systematic review and meta-analysis. *Surg Obes Relat Dis*. 2016;12(5):1116-25.
12. Bright T, Watson DI, Tam W, et al. Prospective randomized trial of argon plasma coagulation ablation versus endoscopic surveillance of Barrett's esophagus in patients treated with antisecretory medication. *Dig Dis Sci*. 2009;54(12):2606-11.
13. Bright T, Watson DI, Tam W, et al. Randomized trial of argon plasma coagulation versus endoscopic surveillance for barrett esophagus after antireflux surgery: late results. *Ann Surg*. 2007;246(6):1016-20.
14. Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. *Am J Gastroenterol*. 2013;108(1):18-37; quiz 8.
15. Carabotti M, Avallone M, Cereatti F, et al. Usefulness of Upper Gastrointestinal Symptoms as a Driver to Prescribe Gastrosocopy in Obese Patients Candidate to Bariatric Surgery. A Prospective Study. *Obesity surgery*. 2016;26(5):1075-80. PMID: 26328530
16. Castro R, Pimentel-Nunes P, Dinis-Ribeiro M. Evaluation and management of gastric epithelial polyps. *Baillieres Best Pract Res Clin Gastroenterol*. 2017;31(4):381-7.
17. Chadwick G, Groene O, Markar SR, et al. Systematic review comparing radiofrequency ablation and complete endoscopic resection in treating dysplastic Barrett's esophagus: a critical assessment of histologic outcomes and adverse events. *Gastrointest Endosc*. 2014;79(5):718-31.e3.
18. Chandrasekar VT, Hamade N, Desai M, et al. Significantly lower annual rates of neoplastic progression in short- compared to long-segment non-dysplastic Barrett's esophagus: a systematic review and meta-analysis. *Endoscopy*. 2019;51(7):665-72.
19. Chen JW, Kao JY. Eosinophilic esophagitis: update on management and controversies. *BMJ*. 2017;359:j4482.
20. Chey WD, Leontiadis GI, Howden CW, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. *Am J Gastroenterol*. 2017;112(2):212-39.
21. Choi AY, Strate LL, Fix MC, et al. Association of gastric intestinal metaplasia and East Asian ethnicity with the risk of gastric adenocarcinoma in a U.S. population. *Gastrointest Endosc*. 2018;87(4):1023-8.
22. Coriat R, Mozer M, Caux F, et al. Endoscopic findings in Cowden syndrome. *Endoscopy*. 2011;43(8):723-6.
23. de Bortoli N, Penagini R, Savarino E, et al. Eosinophilic esophagitis: Update in diagnosis and management. Position paper by the Italian Society of Gastroenterology and Gastrointestinal Endoscopy (SIGE). *Dig Liver Dis*. 2017;49(3):254-60.
24. de Latour RA, Kilaru SM, Gross SA. Management of small bowel polyps: A literature review. *Baillieres Best Pract Res Clin Gastroenterol*. 2017;31(4):401-8.
25. Dellon E, Liacouras C, Molina-Infante J, et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. *Gastroenterology*. 2018;155(4):1022-33.e10.
26. Dellon ES, Gonsalves N, Hirano I, et al. ACG Clinical Guideline: Evidence Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis (EoE). *Am J Gastroenterol*. 2013;108(5):679-92.
27. den Hollander WJ, Holster IL, den Hoed CM, et al. Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions. *Gut*. 2019;68(4):585-93.
28. Desai M, Saligram S, Gupta N, et al. Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett's esophagus-related neoplasia: a systematic review and pooled analysis. *Gastrointest Endosc*. 2017;85(3):482-95.e4.
29. Di Lorenzo N, Antoniou SA, et al. Clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) on bariatric surgery: update 2020 endorsed by IFSO-EC, EASO and ESPCOP. *Surg Endosc*. 2020 Jun;34(6):2332-2358.
30. Dinis-Ribeiro M, Kuipers EJ. How to Manage a Patient With Gastric Intestinal Metaplasia: An International Perspective. *Gastroenterology*. 2020;158(6):1534-7.
31. Durno CB, C. R.; Cohen, S.; Dominitz, J. A.; Giardiello, F. M.; Johnson, D. A.; Kaltenbach, T.; Levin, T. R.; Lieberman, D.; Robertson, D. J.; Rex, D. K. Recommendations on surveillance and management of biallelic mismatch repair deficiency (BMMRD) syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. *Gastrointest Endosc*. 2017;85(5):873-82.
32. El-Serag HB, Kao JY, Kanwal F, et al. Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. *Clin Gastroenterol Hepatol*. 2018;16(7):992-1002.e6.

33. Fujii-Lau LL, Cinnor B, Shaheen N, et al. Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett's esophagus: a systematic review and meta-analysis. *Endosc Int Open*. 2017;5(6):E430-e49.
34. Furuta GT, Katzka DA. Eosinophilic Esophagitis. *N Engl J Med*. 2015;373(17):1640-8.
35. Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. *Hepatology* (Baltimore, Md). 2017;65(1):310-35.
36. Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis. *Am J Gastroenterol*. 2007;102(9):2086-102
37. Gawron AJ, Shah SC, Altayar O, et al. AGA Technical Review on Gastric Intestinal Metaplasia-Natural History and Clinical Outcomes. *Gastroenterology*. 2020;158(3):705-31.e5.
38. Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. *Am J Gastroenterol*. 2014;109(8):1159-79.
39. Goddard AF, Badreldin R, Pritchard DM, et al. The management of gastric polyps. *Gut*. 2010;59(9):1270-6.
40. Godwin B, Wilkins B, Muir AB. EoE disease monitoring: Where we are and where we are going. *Ann Allergy Asthma Immunol*. 2020;124(3):240-7.
41. Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. *Clin Gastroenterol Hepatol*. 2006;4(12):1452-8.
42. Greene CL, Worrell SG, Attwood SE, et al. Emerging Concepts for the Endoscopic Management of Superficial Esophageal Adenocarcinoma. *J Gastrointest Surg*. 2016;20(4):851-60.
43. Gupta S, Li D, El Serag HB, et al. AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia. *Gastroenterology*. 2020;158(3):693-702
44. Gupta S, Tao L, Murphy JD, et al. Race/Ethnicity-, Socioeconomic Status-, and Anatomic Subsite-Specific Risks for Gastric Cancer. *Gastroenterology*. 2019;156(1):59-62.e4.
45. Hamade N, Vennelaganti S, Parasa S, et al. Lower Annual Rate of Progression of Short-Segment vs Long-Segment Barrett's Esophagus to Esophageal Adenocarcinoma. *Clin Gastroenterol Hepatol*. 2019;17(5):864-8.
46. Hanna SR, A.; Weston, A. P.; Totta, F.; Schmitz, R.; Mathur, S.; McGregor, D.; Cherian, R.; Sharma, P. Detection of Barrett's esophagus after endoscopic healing of erosive esophagitis. *Am J Gastroenterol*. 2006;101(7):1416-20.
47. Heald B, Mester J, Rybicki L, et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. *Gastroenterology*. 2010;139(6):1927-33.
48. Hirano I, Chan ES, Rank MA, et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. *Gastroenterology*. 2020;158(6):1776-86.
49. Hirano I, Furuta GT. Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis. *Gastroenterology*. 2020;158(4):840-51.
50. Huang RJ, Choi AY, Truong CD, et al. Diagnosis and Management of Gastric Intestinal Metaplasia: Current Status and Future Directions. *Gut Liver*. 2019;13(6):596-603.
51. Huang RJ, Ende AR, Singla A, et al. Prevalence, risk factors, and surveillance patterns for gastric intestinal metaplasia among patients undergoing upper endoscopy with biopsy. *Gastrointest Endosc*. 2020;91(1):70-7.e1.
52. Islam RS, Patel NC, Lam-Himlin D, et al. Gastric polyps: a review of clinical, endoscopic, and histopathologic features and management decisions. *Gastroenterology & hepatology*. 2013;9(10):640-51.
53. Kahaleh M, Van Laethem JL, Nagy N, et al. Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression. *Endoscopy*. 2002;34(12):950-5.
54. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. *Gastroenterology*. 2008;135(4):1383-91, 91.e1-5.
55. Kastelein F, Spaander MC, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. *Clin Gastroenterol Hepatol*. 2013;11(4):382-8
56. Katona BW, Powers J, McKenna DB, et al. Upper Gastrointestinal Cancer Risk and Surveillance Outcomes in Li-Fraumeni Syndrome. *Am J Gastroenterol*. 2020;115(12):2095-7. PMID: 32969947
57. Katz PO, Gerson LB, Vela MF. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. *Am J Gastroenterol*. 2013;108(3).
58. Kavitt RT, Ates F, Slaughter JC, et al. Randomized controlled trial comparing esophageal dilation to no dilation among adults with esophageal eosinophilia and dysphagia. *Dis Esophagus*. 2016;29(8):983-91
59. Kely CJ, Ackroyd R, Brown NJ, et al. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. *Aliment Pharmacol Ther*. 2004;20(11-12):1289-96
60. Keyashian K, Hua V, Narsinh K, et al. Barrett's esophagus in Latinos undergoing endoscopy for gastroesophageal reflux disease symptoms. *Dis Esophagus*. 2013;26(1):44-9.

61. Kim J, Braun D, Ukaegbu C, et al. Clinical Factors Associated With Gastric Cancer in Individuals With Lynch Syndrome. *Clin Gastroenterol Hepatol*. 2020;18(4):830-7.e1.
62. Ko CW, Siddique SM, Patel A, et al. AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia. *Gastroenterology*. 2020;159(3):1085-94.
63. Kohoutova D, Haidry R, Banks M, et al. Long-term outcomes of the randomized controlled trial comparing 5-aminolaevulinic acid and Photofrin photodynamic therapy for Barrett's oesophagus related neoplasia. *Scand J Gastroenterol*. 2018;53(5):527-32.
64. Komanduri S, Kahrilas PJ, Krishnan K, et al. Recurrence of Barrett's Esophagus is Rare Following Endoscopic Eradication Therapy Coupled With Effective Reflux Control. *Am J Gastroenterol*. 2017;112(4):556-66.
65. Krishnamoorthi R, Singh S, Ragunathan K, et al. Risk of recurrence of Barrett's esophagus after successful endoscopic therapy. *Gastrointest Endosc*. 2016;83(6):1090-106.e3.
66. Laine L, Jensen DM. ACG clinical guideline: Management of Patients With Ulcer Bleeding. *Am J Gastroenterol*. 2012;107(3).
67. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol*. 2018;113(4):481-517.
68. Ma C, van Rhijn BD, Jairath V, et al. Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. *Clin Gastroenterol Hepatol*. 2018;16(11):1714-29.e3.
69. Manner H, Rabenstein T, Pech O, et al. Ablation of residual Barrett's epithelium after endoscopic resection: a randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study). *Endoscopy*. 2014;46(1):6-12.
70. Mari A, Abu Baker F, Mahamid M, et al. Eosinophilic esophagitis: pitfalls and controversies in diagnosis and management. *Minerva Med*. 2020;111(1):9-17.
71. Mechanick JL, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. *Surg Obes Relat Dis*. 2020;16(2):175-247.
72. Mester J, Eng C. Cowden syndrome: recognizing and managing a not-so-rare hereditary cancer syndrome. *J Surg Oncol*. 2015;111(1):125-30.
73. Moawad FJ, Dellon ES, Achem SR, et al. Effects of Race and Sex on Features of Eosinophilic Esophagitis. *Clin Gastroenterol Hepatol*. 2016;14(1):23-30.
74. Moayyedi PM, Lacy BE, Andrews CN, et al. ACG and CAG Clinical Guideline: Management of Dyspepsia. *Am J Gastroenterol*. 2017;112(7).
75. Modiano NG, L. B. Risk factors for the detection of Barrett's esophagus in patients with erosive esophagitis. *Gastrointest Endosc*. 2009;69(6):1014-20.
76. Møller P, Seppälä TT, Bernstein I, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. *Gut*. 2018;67(7):1306-16.
77. Moole H, Jacob K, Duvvuri A, et al. Role of endoscopic esophageal dilation in managing eosinophilic esophagitis: A systematic review and meta-analysis. *Medicine (Baltimore)*. 2017;96(14):e5877.
78. National Comprehensive Cancer Network. Neuroendocrine and Adrenal Tumors, Version 2.2022 NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network; 2022. P 187.
79. National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network; 2023. p. 55
80. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network; 2023. p. 168.
81. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 4.2024, Familial Adenomatous Polyposis, NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network; 2024. p. 21-22.
82. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network; 2023. p. 148.
83. National Comprehensive Cancer Network, Ajani J, D'Amico T, et al. Gastric Cancer, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network; 2023. p. 136.
84. National Comprehensive Cancer Network, Ajani JA, D'Amico TA, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network; 2023. p. 166.
85. National Comprehensive Cancer Network, Benson AB, Venook AP, et al. Small Bowel Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network; 2023. p. 54
86. National Comprehensive Cancer Network, Zelenetz AD, Gordon LI, et al. B-Cell Lymphomas, Version 5.2023, NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network; 2023. p. 324.
87. National Institutes of Health (NIH). National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. Bethesda (MD): U.S. Department of Health and Human Services; 2021.

88. Nayar DS, Vaezi MF. Classifications of esophagitis: who needs them? *Gastrointest Endosc.* 2004;60(2):253-7.
89. Nhu QM, Aceves SS. Medical and dietary management of eosinophilic esophagitis. *Ann Allergy Asthma Immunol.* 2018;121(2):156-61.
90. Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-analysis. *Clin Gastroenterol Hepatol.* 2013;11(10):1245-55.
91. Oude Nijhuis RAB, Zaninotto G, Roman S, et al. European guidelines on achalasia: United European Gastroenterology and European Society of Neurogastroenterology and Motility recommendations. *United European Gastroenterol J.* 2020;8(1):13-33.
92. Pabla BS, Shah SC, Corral JE, et al. Increased Incidence and Mortality of Gastric Cancer in Immigrant Populations from High to Low Regions of Incidence: A Systematic Review and Meta-Analysis. *Clin Gastroenterol Hepatol.* 2020;18(2):347-59.e5.
93. Parikh M, Liu J, Vieira D, et al. Preoperative Endoscopy Prior to Bariatric Surgery: a Systematic Review and Meta-Analysis of the Literature. *Obes surg.* 2016;26(12):2961-6.
94. Park WG, Shaheen NJ, ASGE/ACG Task Force on Quality in Endoscopy, et al. Quality indicators for EGD. *Am J Gastroenterol.* 2015;110(1):60-71.
95. Pasricha S, Bulsiewicz WJ, Hathorn KE, et al. Durability and predictors of successful radiofrequency ablation for Barrett's esophagus. *Clin Gastroenterol Hepatol.* 2014;12(11):1840-7.e1.
96. Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. *Jama.* 2014;311(12):1209-17.
97. Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. *Endoscopy.* 2019;51(4):365-88.
98. Qumseya BJ, Bukannan A, Gendy S, et al. Systematic review and meta-analysis of prevalence and risk factors for Barrett's esophagus. *Gastrointest Endosc.* 2019;90(5):707-17.e1.
99. Qumseya BJ, Wani S, Gendy S, et al. Disease Progression in Barrett's Low-Grade Dysplasia With Radiofrequency Ablation Compared With Surveillance: Systematic Review and Meta-Analysis. *Am J Gastroenterol.* 2017;112(6):849-65.
100. Rank MA, Sharaf RN, Furuta GT, et al. Technical Review on the Management of Eosinophilic Esophagitis: A Report From the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters. *Gastroenterology.* 2020;158(6):1789-810.e15.
101. Rodriguez SM, N.; Lieberman, D.; Fennerty, B.; Eisen, G. Barrett's esophagus on repeat endoscopy: should we look more than once? *Am J Gastroenterol.* 2008;103(8):1892-7.
102. Rubenstein JHE, R.; Heidelbaugh, J.; Barkun, A. American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Lynch Syndrome. *Gastroenterology.* 2015;149(3):777-82; quiz e16-7.
103. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. *Am J Gastroenterol.* 2019;114(3):384-413.
104. Rubio-Tapia A, Hill ID, Kelly CP, et al. American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease. *Am J Gastroenterol.* 2023 Jan 1;118(1):59-76.
105. Rubio-Tapia A, Rahim MW, See JA, et al. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. *Am J Gastroenterol.* 2010;105(6):1412-20.
106. Saarinen T, Kettunen U, Pietiläinen KH, et al. Is preoperative gastroscopy necessary before sleeve gastrectomy and Roux-en-Y gastric bypass? *Surg Obes Relat Dis.* 2018;14(6):757-62. PMID: 29477376
107. Schreiberman IRB, M.; Amos, C.; McGarrity, T. J. The hamartomatous polyposis syndromes: a clinical and molecular review. *Am J Gastroenterol.* 2005;100(2):476-90.
108. Sengupta N, Feuerstein JD, Jairath V, Shergill AK, Strate LL, Wong RJ, Wan D. Management of Patients With Acute Lower Gastrointestinal Bleeding: An Updated ACG Guideline. *Am J Gastroenterol.* 2023;118(2):208-231.
109. Shaheen NJ, Falk GW, Iyer PG, Souza RF, Yadlapati RH, Sauer BG, Wani S. Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. *Am J Gastroenterol.* 2022;117(4):559-587. PMID: 35354777
110. Shaheen NJ, Fennerty MB, Bergman JJ. Less Is More: A Minimalist Approach to Endoscopy. *Gastroenterology.* 2018;154(7):1993-2003.
111. Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. *Gastroenterology.* 2011;141(2):460-8.
112. Shao L, Li P, Ye J, et al. Risk of gastric cancer among patients with gastric intestinal metaplasia. *Int J Cancer.* 2018;143(7):1671-7.
113. Sharma P, Shaheen NJ, Katzka D, et al. AGA Clinical Practice Update on Endoscopic Treatment of Barrett's Esophagus With Dysplasia and/or Early Cancer: Expert Review. *Gastroenterology.* 2020;158(3):760-9.
114. Sie C, Bright T, Schoeman M, et al. Argon plasma coagulation ablation versus endoscopic surveillance of Barrett's esophagus: late outcomes from two randomized trials. *Endoscopy.* 2013;45(11):859-65.

115. Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. *Cochrane Database Syst Rev.* 2013;2013(5):Cd002095.
116. Singh S, Garg SK, Singh PP, et al. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. *Gut.* 2014;63(8):1229-37.
117. Slater BJ, Collings A, Dirks R, et al. Multi-society consensus conference and guideline on the treatment of gastroesophageal reflux disease (GERD). *Surg Endosc.* 2023;37(2):781-806.
118. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. *Gastroenterology.* 2011;140(3):1084-91.
119. Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. *Gut Liver.* 2017;11(1):27-37.
120. Syngal S, Brand RE, Church JM, et al. ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes. *Am J Gastroenterol.* 2015;110(2).
121. Talley NJ. American Gastroenterological Association medical position statement: evaluation of dyspepsia. *Gastroenterology.* 2005;129(5):1753-5.
122. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE), Banerjee S, Cash BD, et al. The role of endoscopy in the management of patients with peptic ulcer disease. *Gastrointest Endosc.* 2010;71(4):663-8.
123. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE), Chathadi KV, Khashab MA, et al. The role of endoscopy in ampullary and duodenal adenomas. *Gastrointest Endosc.* 2015;82(5):773-81.
124. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE), Evans J, Muthusamy V, et al. The role of endoscopy in the bariatric surgery patient. *Surg Endosc.* 2015;29(5):1007-17.
125. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE), Evans JA, Chandrasekhara V, et al. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. *Gastrointest Endosc.* 2015;82(1):1-8.
126. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE), Evans JA, Early DS, et al. The role of endoscopy in the assessment and treatment of esophageal cancer. *Gastrointest Endosc.* 2013;77(3):328-34.
127. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE), Evans JA, Early DS, et al. The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus. *Gastrointest Endosc.* 2012;76(6):1087-94.
128. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE), Fukami N, Anderson MA, et al. The role of endoscopy in gastroduodenal obstruction and gastroparesis. *Gastrointest Endosc.* 2011;74(1):13-21.
129. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE), Hwang JH, Fisher DA, et al. The role of endoscopy in the management of acute non-variceal upper GI bleeding. *Gastrointest Endosc.* 2012;75(6):1132-8.
130. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE), Hwang JH, Shergill AK, et al. The role of endoscopy in the management of variceal hemorrhage. *Gastrointest Endosc.* 2014;80(2):221-7.
131. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE), Khashab MA, Vela MF, et al. ASGE guideline on the management of achalasia. *Gastrointest Endosc.* 2020;91(2):213-27.e6.
132. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE), Muthusamy VR, Lightdale JR, et al. The role of endoscopy in the management of GERD. *Gastrointest Endosc.* 2015;81(6):1305-10.
133. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE), Pasha SF, Acosta RD, et al. The role of endoscopy in the evaluation and management of dysphagia. *Gastrointest Endosc.* 2014;79(2):191-201.
134. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE), Qumseya B, Sultan S, et al. ASGE guideline on screening and surveillance of Barrett's esophagus. *Gastrointest Endosc.* 2019;90(3):335-59.e2.
135. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE), Shaukat A, Wang A, et al. The role of endoscopy in dyspepsia. *Gastrointest Endosc.* 2015;82(2):227-32.
136. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE), Shergill AK, Lightdale JR, et al. The role of endoscopy in inflammatory bowel disease. *Gastrointest Endosc.* 2015;81(5):1101-21.e1-13.
137. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE), Wang A, Shaukat A, et al. Race and ethnicity considerations in GI endoscopy. *Gastrointest Endosc.* 2015;82(4):593-9.
138. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE), Wani S, Qumseya B, et al. Endoscopic eradication therapy for patients with Barrett's esophagus-associated dysplasia and intramucosal cancer. *Gastrointest Endosc.* 2018;87(4):907-31.e9.
139. Vaezi MF, Pandolfino JE, Yadlapati RH, et al. ACG Clinical Guidelines: Diagnosis and Management of Achalasia. *Am J Gastroenterol.* 2020;115(9).
140. Vakil N, Moayyedi P, Fennerty MB, et al. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. *Gastroenterology.* 2006;131(2):390-401; quiz 659-60.

141. van Pinxteren B, Sigterman KE, Bonis P, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. *Cochrane Database Syst Rev*. 2010(11):Cd002095.
142. Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. *Gut*. 2013;62(6):812-23.
143. Visrodia K, Singh S, Krishnamoorthi R, et al. Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis. *Gastroenterology*. 2016;150(3):599-607.e7; quiz e14-5.
144. Visrodia K, Zakko L, Singh S, et al. Cryotherapy for persistent Barrett's esophagus after radiofrequency ablation: a systematic review and meta-analysis. *Gastrointest Endosc*. 2018;87(6):1396-404.e1.
145. Wani S, Qumseya B, Sultan S, et al. Endoscopic eradication therapy for patients with Barrett's esophagus-associated dysplasia and intramucosal cancer. *Gastrointest Endosc*. 2018;87(4):907-31.e9.
146. Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett's esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. *Endoscopy*. 2017;49(2):191-8.
147. Wong CJ. Involuntary weight loss. *Med Clin North Am*. 2014;98(3):625-43.
148. Younes M, Lauwers GY, Ertan A, et al. The significance of "indefinite for dysplasia" grading in Barrett metaplasia. *Archives of pathology & laboratory medicine*. 2011;135(4):430-2.
149. Yue H, Shan L, Bin L. The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis. *Gastric cancer*. 2018;21(4):579-87

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Neuroendocrine and Adrenal Tumors, V2.2022. Available at: <http://www.nccn.org>. Accessed July 18, 2023. ©National Comprehensive Cancer Network, 2022. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Gastrointestinal Stromal Tumors, V1.2023. Available at: <http://www.nccn.org>. Accessed July 18, 2023. ©National Comprehensive Cancer Network, 2023. To view the most recent and complete version of the Guidelines, go online to www.nccn.org.

These Guidelines are a work in progress that may be refined as often as new significant data becomes available.

The NCCN Guidelines® are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Codes

The following code list is not meant to be all-inclusive. Authorization requirements will vary by health plan. Please consult the applicable health plan for guidance on specific procedure codes.

Medical necessity reviews are initiated by submitting the correct AMA CPT codes. Specific CPT codes for services should be used when available. The submitted codes must accurately identify the service or procedure to be performed. If no such code exists, contact the health plan directly and report the service or procedure using the appropriate unlisted procedure or Not Otherwise Classified (NOC) code (which often ends in 99). Do not submit a code that is "close to" the procedure performed in lieu of an unlisted code. Correct coding demands that the code reported is appropriate for the service provided (i.e., a code that most accurately represents the service provided), and not a code that is similar but represents another service. (*CPT® Assistant*, December 2010) Nonspecific or NOC codes may be subject to additional documentation requirements and review.

CPT/HCPCS

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five-digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

43229	Esophagoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)
43233	Esophagogastroduodenoscopy, flexible, transoral; with dilation of esophagus with balloon (30 mm diameter or larger) (includes fluoroscopic guidance, when performed)
43235	Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)
43236	Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple

43241	Esophagogastroduodenoscopy, flexible, transoral; with insertion of intraluminal tube or catheter
43243	Esophagogastroduodenoscopy, flexible, transoral; with injection sclerosis of esophageal/gastric varices
43244	Esophagogastroduodenoscopy, flexible, transoral; with band ligation of esophageal/gastric varices
43245	Esophagogastroduodenoscopy, flexible, transoral; with dilation of gastric/duodenal stricture(s) (eg, balloon, bougie)
43246	Esophagogastroduodenoscopy, flexible, transoral; with directed placement of percutaneous gastrostomy tube
43247	Esophagogastroduodenoscopy, flexible, transoral; with removal of foreign body(s)
43248	Esophagogastroduodenoscopy, flexible, transoral; with insertion of guide wire followed by passage of dilator(s) through esophagus over guide wire
43249	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic balloon dilation of esophagus (less than 30 mm diameter)
43250	Esophagogastroduodenoscopy, flexible, transoral; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps
43251	Esophagogastroduodenoscopy, flexible, transoral; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique
43254	Esophagogastroduodenoscopy, flexible, transoral; with endoscopic mucosal resection
43255	Esophagogastroduodenoscopy, flexible, transoral; with control of bleeding, any method
43266	Esophagogastroduodenoscopy, flexible, transoral; with placement of endoscopic stent (includes pre- and post-dilation and guide wire passage, when performed)
43270	Esophagogastroduodenoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)
0652T	Esophagogastroduodenoscopy, flexible, transnasal; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)
0653T	Esophagogastroduodenoscopy, flexible, transnasal; with biopsy, single or multiple
0654T	Esophagogastroduodenoscopy, flexible, transnasal; with insertion of intraluminal tube or catheter
C1726	Catheter, balloon dilatation, non-vascular

Excluded: Endoscopic Ultrasound

43231	Esophagoscopy, flexible, transoral; with endoscopic ultrasound examination
43232	Esophagoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s)
43237	Esophagogastroduodenoscopy, flexible, transoral; with endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent structures
43238	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s), (includes endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent structures)
43242	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis)
43259	Esophagogastroduodenoscopy, flexible, transoral; with endoscopic ultrasound examination, including the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis

Excluded: Placement of pH Probe

91034	Esophagus, gastroesophageal reflux test; with nasal catheter pH electrode(s) placement, recording, analysis and interpretation
91035	Esophagus, gastroesophageal reflux test; with mucosal attached telemetry pH electrode placement, recording, analysis and interpretation
91038	Esophageal function test, gastroesophageal reflux test with nasal catheter intraluminal impedance electrode(s) placement, recording, analysis and interpretation; prolonged (greater than 1 hour, up to 24 hours)

ICD-10 Diagnosis

Refer to the ICD-10 CM manual

History

Status	Review Date	Effective Date	Action
Updated codes 07/01/2026	n/a	Unchanged	Added CPT code 43229 and HCPCS code C1726.
Reaffirmed	04/15/2026	Unchanged	Independent Multispecialty Physician Panel (IMPP) review. Guideline reaffirmed.
Revised	07/17/2025	04/04/2026	IMPP review. Clarified when endoscopy is appropriate for individuals with Barrett's esophagus and for follow-up surveillance endoscopy. Clarified when endoscopy is appropriate when a GI source of occult bleeding is suspected and to guide treatment of celiac disease. Added dupilumab as new therapy for eosinophilic esophagitis. Added new scenarios for management of T1b esophageal adenocarcinoma. Clarified surveillance of non-bleeding varices with high-risk stigmata. Removed excess language and annual requirements for gastric malignancies. Clarified surveillance for type 3 gastric neuroendocrine tumors and removal of additional surveillance. Clarified surveillance for familial adenomatous polyposis (FAP) and attenuated-FAP. For Lynch syndrome, aligned with NCCN guidelines and added screening and surveillance of MSH6 mutation. Clarified surveillance for juvenile polyposis syndrome and hereditary diffuse gastric cancer. Added medical necessity criteria for H. pylori. Added references.
Created	07/10/2024 and 07/13/2023; IMPP 08/31/2021	11/01/2024	Literature reviewed. Added references. IMPP review. Added codes. Original effective date.